Q-omics provides the consensus-scored ZZZ3 profile across patient tissues and cancer cell-line models. ZZZ3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZZZ3 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ZZZ3 RNA expression shows 20,784 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where ZZZ3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZZZ3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZZZ3 survival associations across molecular data types. ZZZ3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZZZ3 RNA expression–survival associations across cancer types. High ZZZ3 expression shows unfavorable associations in LGG, LIHC, ACC and LUSC, but favorable associations in KIRC and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZZZ3 RNA expression.
This table summarizes ZZZ3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZZZ3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZZZ3 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, BLCA and STAD. The HNSC box plot shows higher ZZZ3 RNA expression in tumor versus normal tissue (log2 FC = +0.653, t-test p < 0.001).
This table shows molecular features associated with ZZZ3 in patient tissues and cancer cell lines. In patient samples, ZZZ3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZZZ3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
